362 related articles for article (PubMed ID: 34587359)
1. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H; Kenmotsu H; Kawabata T; Notsu A; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T
Cancer Med; 2021 Nov; 10(21):7503-7513. PubMed ID: 34587359
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
[TBL] [Abstract][Full Text] [Related]
4. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
[TBL] [Abstract][Full Text] [Related]
6. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581
[TBL] [Abstract][Full Text] [Related]
7. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
13. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
[TBL] [Abstract][Full Text] [Related]
17. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
[TBL] [Abstract][Full Text] [Related]
18. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
19. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
20. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.
Sun H; Ren P; Chen Y; Lan L; Yan Z; Yang Y; Wang B; Wang C; Li Y; Li L; Zhang Y; Li Y; Wang Z; Pan Z; Jiang Z
BMC Cancer; 2023 Mar; 23(1):198. PubMed ID: 36864384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
